Pre-emptive pain medication/postoperative pain control Signs and Symptoms Pain
Conditions
Interventions
This is a prospective, randomized, double-blind, placebo-controlled study to compare total morphine consumption between the pre-emptive gabapentin, the postoperative gabapentin and the placebo groups.
Sponsors
Sunnybrook Health Sciences Centre (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Upon obtaining informed consent, patients with American Society of Anesthesiologists physical status I and II, of both genders, scheduled for hip arthroplasty will be recruited for this double-blinded, prospective, randomized, and placebo-controlled study. Patients must also be 18?70 years of age.
Exclusion criteria
Exclusion criteria: 1. Patients not providing informed consent 2. Patients less than 18 years of age and greater than 75 years of age 3. Known allergy to any of the medications being used 4. History of drug or alcohol abuse 5. Patients with chronic pain on slow-release preparations of opioid 6. Patients with rheumatoid arthritis 7. Patients with psychiatric disorders 8. Patients unable or unwilling to use patient-controlled analgesia 9. Diabetic patients or those with impaired renal function (creatinine >106) 10. Obese patients (i.e., body mass index [BMI] >40)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A comparison of the means of morphine consumption among the various treatment groups will be the primary outcome measure. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Visual Analog Scale (VAS) for pain will be used (0 = no pain, 100 = terrible pain) 2. Presence of nausea, vomiting, pruritis, and dizziness will be monitored at the same time intervals, and all except the latter treated as per the Acute Pain Service Nausea and Vomiting algorithm | — |
Countries
Canada
Outcome results
None listed